Compare EXLS & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXLS | SRRK |
|---|---|---|
| Founded | 1999 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 5.2B |
| IPO Year | 2004 | 2018 |
| Metric | EXLS | SRRK |
|---|---|---|
| Price | $43.25 | $43.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 18 |
| Target Price | $48.63 | ★ $70.44 |
| AVG Volume (30 Days) | ★ 2.4M | 1.6M |
| Earning Date | 10-27-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.27 | N/A |
| EPS | ★ 1.30 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.77 | N/A |
| Revenue Next Year | $12.94 | $565.83 |
| P/E Ratio | $33.16 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $24.85 | $35.53 |
| 52 Week High | $44.36 | $61.76 |
| Indicator | EXLS | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 64.48 | 45.41 |
| Support Level | $28.95 | $38.72 |
| Resistance Level | N/A | $51.59 |
| Average True Range (ATR) | 1.20 | 2.44 |
| MACD | -0.07 | 0.24 |
| Stochastic Oscillator | 80.22 | 20.88 |
ExlService Holdings Inc. is a data analytics and digital operations company that provides data and AI-led solutions and technology-enabled services to clients across industries. The company has four reportable segments. The Insurance segment provides services such as claims management, underwriting support, and analytics solutions. The Healthcare and Life Sciences segment offers data-driven solutions and services to healthcare payers, providers, and life sciences organizations. The Banking, Capital Markets and Diversified Industries segment delivers solutions across financial services and other industries. The International Growth Markets segment focuses on providing data, AI, and digital operations services to clients outside North America.
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.